The short answer
A reporting odds ratio is meaningless without its comparator. Three published FAERS analyses of the same drugs report widely different figures, and the differences come almost entirely from what each one compared against rather than from any disagreement about the data.
Key facts
- What ROR measures
- Odds of an event being reported for a drug, against the same odds in a comparator group
- Comparator option 1
- The entire rest of the database
- Comparator option 2
- A single named drug
- Comparator option 3
- A restricted subpopulation
- Tirzepatide vs semaglutide, AKI
- ROR 0.44 (95% CI 0.38-0.50)
- Semaglutide vs whole database, AKI
- PRR 1.25, ROR 1.25
- Semaglutide vs database, ketoacidosis in non-diabetics
- ROR 3.15 (95% CI 2.78-3.56)
- What none of them measure
- Incidence, risk, or absolute rate
The arithmetic
A spontaneous reporting database contains reports, not patients. For any drug-event pair you can build a two-by-two table: reports of this event for this drug, reports of other events for this drug, reports of this event for everything else, reports of other events for everything else. The reporting odds ratio is the cross-product of that table. The proportional reporting ratio is a closely related quantity built from proportions rather than odds; in practice the two usually agree closely, and where they diverge it is a sign the counts are small. Neither is a rate. There is no denominator of people exposed anywhere in the calculation, so no incidence can be recovered from it.
The same question, three comparators, three answers
Consider acute kidney injury and semaglutide. Gandhi and colleagues compared tirzepatide against semaglutide directly in FAERS reports from January 2022 to September 2025, and found a reporting odds ratio for tirzepatide versus semaglutide of 0.44 (95% CI 0.38 to 0.50). Shokr and colleagues compared each drug against the rest of the database and reported semaglutide with a PRR of 1.25 and ROR of 1.25 for acute kidney injury. Makhmutov and Qureshi restricted to non-diabetic patients and looked at ketoacidosis, finding semaglutide at ROR 3.15 (95% CI 2.78 to 3.56). These are not three estimates of one quantity that happen to disagree. They are three different quantities.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the drug-versus-drug comparison is the sharpest and the most fragile
Comparing one drug against a single named drug rather than against the whole database removes a lot of noise: two agents used for the same indication in similar populations share many of the biases that distort spontaneous reporting. That is why Gandhi's design is the informative one for the question 'do these two differ'. It is also the most fragile, because it inherits every difference between the two drugs' reporting environments: how long each has been marketed, how much media attention each has had, which countries report them, and which one is likelier to be named as primary suspect when a patient takes both. A ROR of 0.44 says tirzepatide reports were less likely to mention acute kidney injury than semaglutide reports. It does not say a patient's kidneys are safer on one than the other.
The absolute numbers are the ones worth quoting
Gandhi's analysis covered 133,872 reports (92,807 for tirzepatide, 41,065 for semaglutide), and acute kidney injury appeared in 432 tirzepatide reports (0.47%) and 440 semaglutide reports (1.07%). Those percentages are the proportion of reports mentioning the event, not the proportion of treated people experiencing it, and the distinction is not pedantic: the reporting fraction for serious events is generally low and unknown, so the true frequency in treated people is unmeasured in either direction. What the numbers do establish is that acute kidney injury is an uncommon thing to find in a report about either drug, and the authors say as much.
What a signal is actually for
A disproportionality signal is a prompt to look, not a finding. It says that a drug-event pair appears together more often than the background pattern would predict, which is a reason to design a study with a denominator (a cohort, a case-control, a self-controlled series) and answer the question properly. Treating the signal itself as the answer inverts the purpose of the system. Every one of the three papers here says so in its own limitations section, and every piece of coverage that quotes the ratio without the comparator strips that out.
The one-line test
If someone quotes a reporting odds ratio to you and you cannot immediately say what it was compared against, over what period, and in which subpopulation, the number has told you nothing. That is not a criticism of the method. It is the method: the ratio is defined relative to a reference group, and the reference group is a choice.
Quick reference
| Analysis | Comparator | Event | Figure reported |
|---|---|---|---|
| Gandhi 2025 | Tirzepatide vs semaglutide | Acute kidney injury | ROR 0.44 (0.38-0.50) |
| Shokr 2026 | Semaglutide vs rest of database | Acute kidney injury | PRR 1.25, ROR 1.25 |
| Shokr 2026 | Semaglutide vs rest of database | Gastrointestinal events | PRR 3.97, ROR 14.21 |
| Makhmutov 2026 | Semaglutide, non-diabetics | Ketoacidosis | ROR 3.15 (2.78-3.56) |
| Makhmutov 2026 | Tirzepatide, non-diabetics | Ketoacidosis | ROR 1.22 (1.06-1.39) |
Frequently asked questions
Does a ROR above 1 mean the drug causes the event?
No. It means reports pairing that drug with that event are more frequent than the reference pattern predicts. Causation requires a study with a denominator, a temporal sequence, and control of confounding, none of which a spontaneous reporting database provides.
Why do PRR and ROR sometimes differ a lot?
They are mathematically close when the event is rare relative to the total. Large divergence, as in the gastrointestinal figures where a PRR of 3.97 sits beside an ROR of 14.21, usually signals that the event makes up a large share of that drug's reports. That is the situation where the odds and the proportion come apart.
Can I compare RORs across two papers?
Only if they used the same comparator, the same time window, the same deduplication and the same event definition. In practice they rarely do, which is why numbers from different FAERS papers should not be lined up in a table without those columns stated.
Is FAERS useless then?
The opposite. It is the fastest system there is for detecting something nobody anticipated, and it has caught real safety problems that no trial would have been large enough to see. It is useless for measuring how often something happens, which is a different job.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedGandhi A et al., Comparative Renal Safety of Tirzepatide and Semaglutide: An FAERS Disproportionality Study - J Clin Med 2025 (PMID 41227073)pubmed.ncbi.nlm.nih.gov
- PubMedShokr H et al., Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems - Pharmaceuticals 2026 (PMID 41599734)pubmed.ncbi.nlm.nih.gov
- PubMedMakhmutov A, Qureshi F, Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity - Cureus 2026 (PMID 42299163)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why a Safety Report Count ClimbsTirzepatide ketoacidosis reports rose from 1-2 per quarter in 2022 to 28-34 by 2025. Almost all of that curve is uptake and reporting behaviour, not risk.
- The Complication That Hides Behind a Normal GlucoseKetoacidosis with near-normal glucose is easy to miss: the test that usually raises the alarm looks reassuring. Both incretin drugs show reporting signals.
- Disclosure Is Not DisqualificationA 2026 obesity meta-analysis declares its sponsor, its employee authors and its paid contractors in full. That transparency is what makes scrutiny possible.
- GDF15: The Same Signal, Wanted and FearedGDF15 acts on a brainstem receptor to suppress appetite. It is an obesity drug target, a cachexia drug target, and a cause of nausea and vomiting in pregnancy.
- PYY(3-36): The Satiety Signal Scaled to the MealPYY is released from the gut after eating, in proportion to the calories consumed. Its active form is produced by the very same enzyme that destroys GLP-1.